Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RWDD3 divergent transcript (RWDD3-DT) is a long non-coding RNA (lncRNA) gene located on human chromosome 1 (chr1:95161676-95234108, hg38)[4][5]. It does not encode a protein but belongs to the class of divergent transcripts associated with, but distinct from, the protein-coding RWDD3 gene[5]. There is no evidence that RWDD3-DT acts as a therapeutic target such as a receptor, enzyme, transporter, or related pharmacological category[4][5]. Current genomic databases (GeneCards, BioGPS, Ensembl) classify RWDD3-DT strictly as a non-coding RNA and not as a traditional druggable target. No common drugs, biomarkers, or mechanisms of action are reported. There are no known safety concerns associated uniquely with the transcript due to its non-coding nature. The functional significance of RWDD3-DT, if any, lies in potential regulatory roles common to lncRNAs, but no widely accepted biological or disease function is described in current sources[4][5]. **Note:** RWDD3-DT should not be confused with the protein-coding gene RWDD3, which has distinct functions and disease associations[2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RWDD3 divergent transcript (RWDD3-DT).